HC Wainwright & Co. Maintains Buy on Leap Therapeutics, Lowers Price Target to $2.5

HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Leap Therapeutics (NASDAQ:LPTX) with a Buy and lowers the price target from $4 to $2.5.

HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Leap Therapeutics (NASDAQ:LPTX) with a Buy and lowers the price target from $4 to $2.5.

Total
0
Shares
Related Posts